The FDA has cleared an AI startup based in Israel to market its predictive-analytics product to ICUs during the present pandemic.
Clew Medical announced the emergency-use authorization June 16, saying its ICU-specific platform can identify patients at heightened risk of developing life-threatening COVID complications such as respiratory failure and hemodynamic instability.
The company says it trained its AI models on nearly 100,000 ICU patients.
The software, called ClewICU, works as a web application and is intended for use in tele-ICU settings as well as local ICUs.
The idea is to give COVID care teams advance warning on patients at greatest risk of serious symptoms, the company adds, which can increase time available for intervening early, planning ahead and allocating resources enterprise- or community-wide.